Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
Top Cited Papers
- 29 January 2016
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (6), 1224-1231
- https://doi.org/10.1016/j.jhep.2016.01.029
Abstract
No abstract availableKeywords
Funding Information
- Gilead UK and Ireland Corporate Contributions
- Medical Research Foundation
- Bristol-Myers Squibb
- Heart of England NHS Foundation Trust
This publication has 14 references indexed in Scilit:
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisHepatology, 2015
- P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use programJournal of Hepatology, 2015
- Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvirJournal of Hepatology, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyThe Lancet, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infectionJournal of Viral Hepatitis, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012